Corbeau P, Benkirane M, Weil R, David C, Emiliani S, Olive D, Mawas C, Serre A, Devaux C
CRBM du CNRS, Centre de Tri des Molécules anti-HIV, Institut de Biologie, Montpellier, France.
J Immunol. 1993 Jan 1;150(1):290-301.
The HIV1 envelope glycoprotein gp120 binding site has been previously mapped by genetic studies to the CDR2-like region of the first domain of the CD4 molecule. mAb reactive with epitopes linked to this region (e.g., OKT4A) inhibit both HIV entry into CD4-positive cells and syncytia formation. A second area of this domain, the CDR3-like region, has been shown to be involved in gp120-CD4 interactions, but its role remained so far unclear. We show here that a mAb specific for the CDR3-like region of the CD4 receptor, 13B8-2, actually blocks soluble gp120 binding to CD4, inhibits HIV-induced cell-cell fusion, and prevents viral production by infected cells. However, this mAb fails to inhibit the binding of viral particles to cell-surface CD4 and their entry into CD4-positive cells. These results strongly suggest i) that soluble gp120 and virion-anchored gp120 bind CD4 in distinct manners, ii) that gp120-CD4 interactions required for viral entry and syncytia formation are different, and iii) that mAb binding to the CDR3-like region of the first domain of CD4 affects a post-entry step of the HIV replicative cycle.
人类免疫缺陷病毒1型包膜糖蛋白gp120的结合位点先前已通过遗传学研究定位到CD4分子第一结构域的类互补决定区2(CDR2-like)区域。与该区域相关表位反应的单克隆抗体(如OKT4A)可抑制HIV进入CD4阳性细胞以及抑制多核巨细胞形成。该结构域的第二个区域,即类互补决定区3(CDR3-like)区域,已显示参与gp120与CD4的相互作用,但迄今为止其作用仍不清楚。我们在此表明,一种针对CD4受体CDR3-like区域的特异性单克隆抗体13B8-2,实际上可阻断可溶性gp120与CD4的结合,抑制HIV诱导的细胞间融合,并阻止受感染细胞产生病毒。然而,该单克隆抗体无法抑制病毒颗粒与细胞表面CD4的结合及其进入CD4阳性细胞。这些结果强烈表明:i)可溶性gp120和病毒体锚定的gp120以不同方式结合CD4;ii)病毒进入和多核巨细胞形成所需的gp120与CD4的相互作用不同;iii)与CD4第一结构域CDR3-like区域结合的单克隆抗体影响HIV复制周期的进入后步骤。